CJ Bioscience Inc
311690
Company Profile
Business description
CJ Bioscience Inc is engaged in directing a healthy life based on microbiological research. It presents directions and solutions to all fields of research on the microbiome, such as academia in the bioinformatics field, R&D centers of hospitals and research institutes, and NGS (next-generation sequencing) service companies. Its services includes NGS, EZBioCloud, Healthcare among others.
Contact
7th floor, Grand Central Building B
14 Sejong-Daero
Jung-gu
Seoul
KORT: +82 260783456
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
129
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.60 | 41.00 | 0.45% |
| CAC 40 | 7,739.62 | 3.38 | -0.04% |
| DAX 40 | 24,113.27 | 49.59 | -0.21% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,131.02 | 35.29 | 0.39% |
| HKSE | 24,888.29 | 29.47 | 0.12% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,911.86 | 67.23 | 0.52% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,844.80 | 37.70 | 0.43% |
| SSE Composite Index | 3,647.55 | 12.42 | 0.34% |